5-methoxy-6-methyl-1-indanone | 67199-56-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 茚满类
• 英文名称: 5-methoxy-6-methyl-1-indanone
• 英文别名: 5-Methoxy-6-methyl-2,3-dihydro-1H-inden-1-one；5-methoxy-6-methyl-2,3-dihydroinden-1-one
• CAS: 67199-56-8
• 化学式: C₁₁H₁₂O₂
• mdl: MFCD11044105
• 分子量: 176.215
• InChiKey: AVWNTIXAZUBPIW-UHFFFAOYSA-N

物化性质

• 熔点：
  114-115 °C(Solv: benzene (71-43-2); hexane (110-54-3))
• 沸点：
  325.0±41.0 °C(Predicted)
• 密度：
  1.134±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.363
• 拓扑面积：
  26.3
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  5-methoxy-6-methyl-1-indanone 在 盐酸 、 亚硝酸异戊酯 作用下， 以 甲醇 为溶剂， 反应 0.75h， 以96.9%的产率得到2-(hydroxyimino)-5-methoxy-6-methyl-1-indanone
  参考文献：
  名称：

  Synthesis and pharmacological examination of 1-(3-methoxy-4-methylphenyl)-2-aminopropane and 5-methoxy-6-methyl-2-aminoindan: similarities to 3,4-(methylenedioxy)methamphetamine (MDMA)

  摘要：

  The racemate and the enantiomers of 1-(3-methoxy-4-methylphenyl)-2-aminopropane (6) and racemic 5-methoxy-6-methyl-2-aminoindan (11) were tested for stimulus generalization in the two-lever drug-discrimination paradigm. Both 6 and 11 were found to substitute with high potency in 3,4-(methylenedioxy)methamphetamine (1) and (S)-1-(1,3-benzodioxol-5-yl)-2-(methylamino)butane (2) trained rats. In the latter assay, both enantiomers of 6 had identical potencies, but their dose-response curves were not parallel. Racemic 6, but not 11, partially substituted for LSD. Racemic 6 and 11 did not substitute in (S)-amphetamine-trained rats. All of the test compounds were potent inhibitors of [H-3]-5-HT uptake into synaptosomes in vitro, with the S enantiomer of 6 being most active. Rat brain monoamine levels were unaltered 1 week following a single high dose (10 or 20 mg/kg, sc) of 6 or 11, or two weeks following a subacute dosing regimen (20 mg/kg, sc, twice a day for 4 days). In addition, radioligand-binding parameters in rat brain homogenate with the 5-HT uptake inhibitor [H-3]proxetine were unchanged after subacute dosing with either racemic 6 or 11. The results indicate that compounds 6 and 11 have animal behavioral pharmacology similar to the methylenedioxy compounds 1 and 2, but that they do not induce the serotonin neurotoxicity that has been observed for the latter two drugs.

  DOI：

  10.1021/jm00109a020
• 作为产物：
  描述：

  4-甲基-3-硝基苯甲醛 在 哌啶 、 吡啶 、 盐酸 、 氯化亚砜 、 乙醇 、 alkaline solution 、 硼酸 、 sodium carbonate 、 铂 作用下， 生成 5-methoxy-6-methyl-1-indanone
  参考文献：
  名称：

  An Investigation of the Mills-Nixon Effect

  摘要：

  DOI：

  10.1021/ja01301a066

文献信息

• [EN] (3,4-DISUBSTITUTED)PROPANOIC CARBOXYLATES AS S1P (EDG) RECEPTOR AGONISTS<br/>[FR] CARBOXYLATES PROPANOIQUES 3,4-DISUSBSTITUES UTILISES EN TANT QU'AGONISTES DU RECEPTEUR S1P (EDG)
  申请人：MERCK & CO INC

  公开号：WO2005058848A1

  公开（公告）日：2005-06-30

  The present invention encompasses compounds of Formula A: A as well as the pharmaceutically acceptable salts thereof. The compounds are S1P1/Edg1 receptor agonists and thus have immunosuppressive, anti-inflammatory and hemostatic activities by modulating leukocyte trafficking, sequestering lymphocytes in secondary lymphoid tissues, and enhancing vascular integrity. The invention is also directed to pharmaceutical compositions containing such compounds and methods of treatment or prevention.

  本发明涵盖了化合物A的公式：A以及其药用可接受的盐。这些化合物是S1P1/Edg1受体激动剂，因此通过调节白细胞的运动、在次生淋巴组织中滞留淋巴细胞以及增强血管完整性而具有免疫抑制、抗炎和止血活性。该发明还涉及含有这些化合物的药物组合物以及治疗或预防的方法。
• Wavelength dependent photoextrusion and tandem photo-extrusion reactions of ninhydrin bis-acetals for the synthesis of 8-ring lactones, benzocyclobutenes and orthoanhydrides
  作者：Wei Sun、Surajit Kayal、William A. T. Raimbach、Xue-Zhong Sun、Mark E. Light、Magnus W. D. Hanson-Heine、Michael W. George、David C. Harrowven

  DOI：10.1039/d1cc06800h

  日期：——

  Ninhydrin bis-acetals give access to 8-ring lactones, benzocyclo-butenes and spirocyclic orthoanhydrides through photoextrusion and tandem photoextrusion reactions. Syntheses of fimbricalyxlactone B, isoshihunine and numerous biologically-relevant heterocycles show the value of the methods, while TA-spectroscopy and TD-DFT studies provide mechanistic insights on their wavelength dependence.

  茚三酮双缩醛通过光挤出和串联光挤出反应获得 8 环内酯、苯并环丁烯和螺环原酸酐。fibricalyxlactone B、异鼠宁和许多生物相关杂环的合成显示了这些方法的价值，而 TA 光谱和 TD-DFT 研究提供了关于其波长依赖性的机理见解。
• (3,4-Disubstituted)Propanoic Carboxylates as Sip (Edg) Receptor Agonists
  申请人：Colandrea Vincent J.

  公开号：US20080249093A1

  公开（公告）日：2008-10-09

  The present invention encompasses compounds of Formula I: as well as the pharmaceutically acceptable salts thereof. The compounds are S1P 1 /Edg1 receptor agonists and thus have immunosuppressive, anti-inflammatory and hemostatic activities by modulating leukocyte trafficking, sequestering lymphocytes in secondary lymphoid tissues, and enhancing vascular integrity. The invention is also directed to pharmaceutical compositions containing such compounds and methods of treatment or prevention.

  本发明涵盖以下I式化合物及其药学上可接受的盐。这些化合物是S1P1 / Edg1受体激动剂，因此通过调节白细胞的转移，将淋巴细胞隔离在二级淋巴组织中，并增强血管完整性，具有免疫抑制，抗炎和止血活性。本发明还涉及含有这些化合物的制药组合物和治疗或预防的方法。
• (3,4-disubstituted)propanoic carboxylates as S1P (Edg) receptor agonists
  申请人：Merck & Co., Inc.

  公开号：US07605171B2

  公开（公告）日：2009-10-20

  The present invention encompasses compounds of Formula I: as well as the pharmaceutically acceptable salts thereof. The compounds are S1P1/Edg1 receptor agonists and thus have immunosuppressive, anti-inflammatory and hemostatic activities by modulating leukocyte trafficking, sequestering lymphocytes in secondary lymphoid tissues, and enhancing vascular integrity. The invention is also directed to pharmaceutical compositions containing such compounds and methods of treatment or prevention.

  本发明涵盖公式I的化合物及其药学上可接受的盐。这些化合物是S1P1 / Edg1受体激动剂，因此通过调节白细胞转移，将淋巴细胞隔离在二级淋巴组织中并增强血管完整性，具有免疫抑制、抗炎和止血活性。本发明还涉及含有这种化合物的制药组合物和治疗或预防的方法。
• Beitr�ge zur Konformationsanalyse der Aryl?Methoxy-Bindung
  作者：Otmar Hofer

  DOI：10.1007/bf00906359

  日期：——